Clinical trials: Seizures, Epileptic
- Condition Seizures, Epileptic
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Seizures, Convulsions
A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy
The purpose of this study is to investigate the influence of topiramate monotherapy on the bone and mineral metabolism markers, and bone density (the amount of mineral per square centimeter of bone ) in female participants with…
- Conditions
- Seizures, Convulsions, Epilepsy, Osteopenia
- Trial name
- NCT01030094
- Testing
- Topiramate, Carbamazepine, Valproic acid
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Janssen Korea, Ltd., Korea
Epilepsy, Seizures
A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
A cross-sectional, national, multicenter, survey-based study to assess the effectiveness of Risk Minimization Measures related to Depakine® (sodium valproate) in Saudi Arabia.
- Trial name
- DEPAKINE PASS (NCT06714448)
- Testing
- Sodium valporate
- Where
- France
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sanofi
Childhood Absence Epilepsy, Absence Seizures
Assessing Comorbidities in Epilepsy Using Eye Movement Recordings
This study wants to make it easier to find kids with a type of epilepsy called childhood absence epilepsy (CAE) who might have problems with ongoing seizures and thinking.
- Conditions
- Childhood Absence Epilepsy, Absence Seizures, Epilepsy Comorbidities
- Trial name
- ACER (NCT06310772)
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eysz, Inc.
Diabetic Peripheral Neuropathy, Fibromyalgia
Pharmacokinetics of Two Formulation of Pregabalin
A Randomized, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of Two Formulations of Pregabalin after Oral Administration in Healthy Volunteers under Fasting Conditions
- Conditions
- Diabetic Peripheral Neuropathy, Fibromyalgia, Partial Seizure Disorder
- Trial name
- NCT03712475
- Testing
- Pregabalin
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Epilepsy, Alzheimer Disease
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
- Conditions
- Epilepsy, Alzheimer Disease, Epilepsy Intractable
- Trial name
- NCT07222878
- Testing
- NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NeuroPro Therapeutics, Inc.
Drug Resistant Epilepsy, Focal Seizure
Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007
This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007.
- Trial name
- NCT06899230
- Testing
- iQ-007
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- iQure Australia Pty Ltd
Epilepsy
Tonicity Monitor For Epilepsy and Hypertonic Disorders
Epilepsy is an episodic disorder which can result in recurrent seizures often associated with hypertonia (muscle stiffening) and myoclonia (involuntary muscle jerking).
- Trial name
- NCT02110589
- Testing
- Epidetect
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vikel Ltd
Epilepsy, Alzheimer Disease
Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.
- Conditions
- Epilepsy, Alzheimer Disease, Epilepsy Intractable
- Trial name
- NCT05503511
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NeuroPro Therapeutics, Inc.
Cardiovascular Diseases, Cardiovascular Diseases Risk
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
Cor360 is an observational study evaluating whether extended wearable electrocardiogram (ECG) data can support broad-spectrum cardiac phenotyping and risk assessment beyond conventional single-purpose ambulatory rhythm…
- Conditions
- Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
- Trial name
- Cor360 (NCT07775976)
- Testing
- COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Seizures, Epilepsy
Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions
The objective of this study was to assess the bioequivalence of a potential generic 600 mg oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, following a single 600 mg…
- Trial name
- NCT00616681
- Testing
- Oxcarbazepine
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Epilepsy
Embrace: Seizure Characterization
The study is intended to characterize sleep, stress, and seizures in daily life with the Empatica Embrace watch and smartphone-based diary-alert system.
- Trial name
- NCT03206502
- Testing
- Embrace + Alert App
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Empatica, Inc.
Epilepsy, Seizures
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
The objective of this study was to assess the bioequivalence of a potential generic 600 mg oxcarbazepine tablet formulation with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, folloiwng a single 600 mg dose…
- Trial name
- NCT00616863
- Testing
- Oxcarbazepine
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Seizures
Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures
This is a Phase IV adjunctive treatment dose-optimization study evaluating the efficacy, safety, and health outcomes of ezogabine/retigabine immediate release (IR) (GW582892) compared with placebo in adult subjects with…
- Trial name
- NCT01721317
- Testing
- Ezogabine/Retigabine IR
- Where
- 11 sites in United States, Greece
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Partial Seizure
An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.
An open label, balanced, randomized, 3×3 latin square design comparing of Brivaracetam sustained-release tablets and Brivaracetam tablets in the oral comparative pharmacokinetic(PK) study in Chinese healthy adult subjects under…
- Trial name
- NCT05622370
- Testing
- Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB), Brivaracetam sustained-release tablets 100mg, Brivaracetam sustained-release tablets 50mg
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.